清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Risankizumab as a Therapeutic Approach for Recalcitrant Pyoderma Gangrenosum

医学 坏疽性脓皮病 皮肤病科 不利影响 单克隆 单克隆抗体 皮质类固醇 中性粒细胞性皮肤病 内科学 外科 免疫学 疾病 抗体
作者
Alessandra Michelucci,Flavia Manzo Margiotta,Giammarco Granieri,Giorgia Salvia,Cristian Fidanzi,Matteo Bevilacqua,Salvatore Panduri,Marco Romanelli,Valentina Dini
出处
期刊:Advances in Skin & Wound Care [Lippincott Williams & Wilkins]
卷期号:37 (5): 276-279 被引量:5
标识
DOI:10.1097/asw.0000000000000129
摘要

ABSTRACT Pyoderma gangrenosum (PG) is a neutrophilic dermatosis that is challenging to diagnose and treat. Clinicians frequently use fast-acting corticosteroids, which are subsequently combined with slower-acting immunosuppressants to progressively taper the corticosteroid dosage. Current research is focused on the use of monoclonal antibodies (mAbs) directed against target molecules involved in the pathogenesis of PG. However, available data on their efficacy are based on sporadic case reports and clinical experiences, so the authors aimed to evaluate the efficacy of risankizumab, an anti-interleukin-23 mAb, in the management of two complex PG cases. The authors enrolled two patients with PG who were already treated with immunosuppressive therapies. Their management was based on the off-label use of an mAb directed against the p19 subunit of interleukin-23: risankizumab. Patients received subcutaneous injections of 150 mg at the start of treatment, at week 4, and then every 10 weeks thereafter. Systemic therapy was combined with local management of ulcers, based on the principles of TIME (tissue, infection, moisture balance, and epithelialization) applied to the inflammatory and noninflammatory phases of PG. Clinical resolution was obtained at week 24 for patient 1 and week 16 for patient 2 and was maintained until week 40, without adverse effects or disease recurrence. These clinical cases demonstrate that risankizumab is a valid tool in terms of efficacy and safety for complicated cases of multirefractory PG when provided in parallel with local personalized wound management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
体贴的小霜完成签到,获得积分10
2秒前
魔幻雅柔完成签到,获得积分10
8秒前
Zephyr完成签到 ,获得积分10
9秒前
11秒前
清新的方盒完成签到 ,获得积分10
13秒前
16秒前
Jannatul完成签到,获得积分10
18秒前
21秒前
pericles发布了新的文献求助10
22秒前
31秒前
40秒前
49秒前
ubless607的应助被科研通管家采纳,获得10
51秒前
怕黑的驳完成签到,获得积分10
51秒前
老猫322完成签到 ,获得积分10
52秒前
54秒前
英俊的傲珊完成签到,获得积分10
57秒前
1分钟前
小橙子完成签到 ,获得积分10
1分钟前
qaplay完成签到 ,获得积分0
1分钟前
1分钟前
白嫖论文完成签到 ,获得积分10
1分钟前
1分钟前
CHME完成签到 ,获得积分10
1分钟前
Z小姐完成签到 ,获得积分10
1分钟前
jiayouliyi完成签到 ,获得积分10
1分钟前
1分钟前
玛卡巴卡爱吃饭完成签到 ,获得积分0
1分钟前
1分钟前
炙热迎天完成签到,获得积分10
1分钟前
SMG完成签到 ,获得积分10
1分钟前
qqq完成签到 ,获得积分0
1分钟前
zy完成签到 ,获得积分10
1分钟前
1分钟前
大意的之柔完成签到,获得积分10
2分钟前
2分钟前
2分钟前
失之东隅完成签到,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185496
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783092
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481346